Julian Harrison
Stock Analyst at BTIG
(2.92)
# 1,334
Out of 4,479 analysts
27
Total ratings
42.11%
Success rate
1.41%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTE Aerovate Therapeutics | Downgrades: Neutral | n/a | $1.62 | - | 4 | Jun 17, 2024 | |
| ABVX Abivax | Initiates: Buy | $43 | $13.50 | +218.52% | 1 | May 20, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $32 → $40 | $23.79 | +68.14% | 2 | May 10, 2024 | |
| TBPH Theravance Biopharma | Initiates: Buy | $21 | $8.32 | +152.40% | 1 | Apr 12, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $50 | $7.09 | +605.22% | 3 | Mar 27, 2024 | |
| ANAB AnaptysBio | Initiates: Buy | $55 | $23.94 | +129.74% | 1 | Feb 26, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Neutral | n/a | $1.14 | - | 3 | Jan 11, 2024 | |
| APGE Apogee Therapeutics | Initiates: Buy | $43 | $38.21 | +12.54% | 1 | Dec 20, 2023 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $4 | $0.96 | +316.67% | 1 | Nov 29, 2023 | |
| MTNB Matinas BioPharma Holdings | Reinstates: Buy | $3 | $0.16 | +1,808.40% | 1 | Oct 11, 2023 | |
| MORF Morphic Holding | Downgrades: Neutral | n/a | $31.28 | - | 2 | Sep 25, 2023 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $41 | $34.59 | +18.53% | 1 | Jul 3, 2023 | |
| VRDN Viridian Therapeutics | Initiates: Buy | $46 | $12.16 | +278.29% | 1 | Jun 14, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Buy | $36 | $40.15 | -10.34% | 1 | Mar 9, 2023 | |
| KROS Keros Therapeutics | Maintains: Buy | $95 → $105 | $42.81 | +145.27% | 2 | Dec 13, 2022 | |
| LQDA Liquidia | Maintains: Buy | $14 → $17 | $11.83 | +43.70% | 1 | Jul 20, 2022 | |
| UTHR United Therapeutics | Initiates: Neutral | n/a | $317.05 | - | 1 | Feb 11, 2022 |
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.62
Upside: -
Abivax
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $13.50
Upside: +218.52%
Spyre Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $23.79
Upside: +68.14%
Theravance Biopharma
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $8.32
Upside: +152.40%
Outlook Therapeutics
Mar 27, 2024
Upgrades: Buy
Price Target: $50
Current: $7.09
Upside: +605.22%
AnaptysBio
Feb 26, 2024
Initiates: Buy
Price Target: $55
Current: $23.94
Upside: +129.74%
Aclaris Therapeutics
Jan 11, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Apogee Therapeutics
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $38.21
Upside: +12.54%
Akebia Therapeutics
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $0.96
Upside: +316.67%
Matinas BioPharma Holdings
Oct 11, 2023
Reinstates: Buy
Price Target: $3
Current: $0.16
Upside: +1,808.40%
Morphic Holding
Sep 25, 2023
Downgrades: Neutral
Price Target: n/a
Current: $31.28
Upside: -
Protagonist Therapeutics
Jul 3, 2023
Reiterates: Buy
Price Target: $41
Current: $34.59
Upside: +18.53%
Viridian Therapeutics
Jun 14, 2023
Initiates: Buy
Price Target: $46
Current: $12.16
Upside: +278.29%
MoonLake Immunotherapeutics
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $40.15
Upside: -10.34%
Keros Therapeutics
Dec 13, 2022
Maintains: Buy
Price Target: $95 → $105
Current: $42.81
Upside: +145.27%
Liquidia
Jul 20, 2022
Maintains: Buy
Price Target: $14 → $17
Current: $11.83
Upside: +43.70%
United Therapeutics
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $317.05
Upside: -